Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Discovery Foundation"


4 mentions found


Recently, DNA analysis of two skeletons from unmarked graves in a Jamestown church revealed that both people were related to West. That connection led researchers to documents proving that one of the men — Captain William West — was illegitimate, born to Thomas West’s spinster aunt, Elizabeth. An X-ray scan (left) of the spangled military sash fringed in silver (right) found in the grave of Captain William West. Jamestown Rediscovery Foundation (Preservation Virginia)Unmarked burials in colonial JamestownResearchers found four unmarked graves at Jamestown in 2014, in an Anglican church that the colonists used from about 1608 to 1616. MPI/Archive Photos/Getty ImagesWhile there wasn’t enough DNA to show immediate family ties, Wenman and Captain West both shared the haplogroup H10e.
Persons: Thomas West, Captain William West —, Thomas West’s, Elizabeth, Captain West, James Fort, , Christine Lee, Lee, Captain William West, Sir Ferdinando Wenman, , Kari Bruwelheid, ” Bruwelheid, Éadaoin Harney, William West’s, , Ferdinando Wenman’s, ” Harney, West’s, Mary Blount, West “, West, Governor Thomas West, Ferdinando Wenman, Michael Lavin, ” Lavin, ” Mindy Weisberger Organizations: CNN, Jamestown Rediscovery, Preservation, University of Mississippi, spangled, Jamestown, Smithsonian National Museum of, Harvard University, MPI, Governor, Jamestown Rediscovery Foundation, Scientific Locations: Jamestown , Virginia, Jamestown, England, Preservation Virginia, Wenman, West, Washington ,, North America
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDr. Fillit on Eli Lilly's Alzheimer's drug: Really having breakthroughs & success for the first timeDr. Howard Fillit, Alzheimer’s Drug Discovery Foundation co-founder and chief science officer, joins 'Squawk Box' to discuss news of FDA panel's approval of Eli Lilly's Alzheimer's drug Donanemab, the future of Alzheimer's treatments, and more.
Persons: Fillit, Eli Lilly's Alzheimer's, Howard Fillit, Eli Lilly's Organizations: Discovery Foundation, FDA
The Dells contributed nearly $976 million to their charitable funds, which distribute gifts to a wide array of charities. Together, the 50 donors on the list contributed a total of $11.9 billion to charity in 2023. Only 23 of the richest Americans on the Forbes 400 list donated enough to appear on the Philanthropy rankings. 13 on the list, they contributed $210 million to the Institute for Protein Innovation, which shares its data with scientists for free. _____Maria Di Mento is a senior reporter and Jim Rendon is a senior writer at the Chronicle of Philanthropy, where you can read the full article.
Persons: Michael Bloomberg, Phil Knight, Penny, Michael Dell, Susan, Bill Gates, Melinda French Gates, Bernie Marcus, Ken Langone, Arthur Blank, , , Renee Kaplan, — Franklin Antonio, Hugh Hoffman, , Tim Springer, Chafen Lu, Diego’s Jay Kahn, Lauder, Sergey Brin’s, Michael J, Robert Kraft, Lucia Woods, David, Kathleen LaCross, Pierre Omidyar, Pam, They’re, John, Laura Arnold, Laura, ” Laura Arnold, Wendy Schmidt, Eric Schmidt, “ Younger, Kaplan, Jeff Sobrato, _____ Maria Di Mento, Jim Rendon, Kay Dervishi Organizations: New, New York City, Nike, Bloomberg, Knights, University of Oregon, Dells, Forbes, Forward, Qualcomm, Summer Science, SETI Institute, ALS Association , University of Cincinnati Foundation, Cincinnati Zoo, Botanical, Nature Center, Yale University, Institute for Protein Innovation, Price Club, Apple, San Diego Foundation, Discovery Foundation, Google, Fox Foundation, Parkinson’s Research, New England Patriots, Foundation, Combat, Ms, Foundation for Women, Chicago Foundation for Women, University of Virginia Darden School of Business, eBay, District of Columbia, Associated Press, Philanthropy Locations: New York, Portland , Oregon, Ohio, Moderna, California, Florida, Texas, Virginia, Washington, Hawaii, Massachusetts
The drug, lecanemab, was associated with a type of brain swelling in 12.6% of trial patients, a side effect previously seen with similar drugs. He suggested that could be because homozygous study patients who were given a placebo fared better than expected. Overall, lecanemab patients benefited by 23% to 26% compared with a placebo on these secondary trial goals. Detailed data from the study were presented at the Clinical Trials on Alzheimer's Disease meeting in San Francisco and published in the New England Journal of Medicine. Dr. Howard Fillit, chief science officer at the Alzheimer’s Drug Discovery Foundation, said doctors always balance the benefits and risks of therapies.
Total: 4